Advances in stem cell therapy for amyotrophic lateral sclerosis.
Letizia MazziniDaniela FerrariPavle R AndjusLeonora BuzanskaRoberto CantelloFabiola De MarchiMaurizio GelatiRashid GiniatullinJoel C GloverMariagrazia GrilliElena N KozlovaMargherita MaioliDinko MitrečićAugustas PivoriunasRosario Sanchez-PernauteAnna SarnowskaAngelo L Vescovinull nullPublished in: Expert opinion on biological therapy (2019)
While data from individual studies are encouraging, stem-cell-based therapies do not yet represent a satisfactory, reliable clinical option. The field will critically benefit from the introduction of well-designed, randomized and reproducible, powered clinical trials. Comparative studies addressing key issues such as the nature, properties, and number of donor cells, the delivery mode and the selection of proper patient populations that may benefit the most from cell-based therapies are now of the essence. Multidisciplinary networks of experts should be established to empower effective translation of research into the clinic.
Keyphrases
- stem cells
- amyotrophic lateral sclerosis
- clinical trial
- cell therapy
- induced apoptosis
- case control
- open label
- double blind
- phase iii
- single cell
- cell cycle arrest
- primary care
- case report
- electronic health record
- randomized controlled trial
- big data
- quality improvement
- mesenchymal stem cells
- machine learning
- oxidative stress
- pi k akt